IL187924A - Immunogenic compositions with n. meningitidis capsular polysaccharides, vaccines and kits including them, processes to make them and their use in manufacture of medicines - Google Patents

Immunogenic compositions with n. meningitidis capsular polysaccharides, vaccines and kits including them, processes to make them and their use in manufacture of medicines

Info

Publication number
IL187924A
IL187924A IL187924A IL18792407A IL187924A IL 187924 A IL187924 A IL 187924A IL 187924 A IL187924 A IL 187924A IL 18792407 A IL18792407 A IL 18792407A IL 187924 A IL187924 A IL 187924A
Authority
IL
Israel
Prior art keywords
immunogenic composition
polysaccharide
meningitidis
capsular
menc
Prior art date
Application number
IL187924A
Other languages
English (en)
Hebrew (he)
Other versions
IL187924A0 (en
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36716943&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL187924(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB0513071.1A external-priority patent/GB0513071D0/en
Priority claimed from GBGB0513069.5A external-priority patent/GB0513069D0/en
Priority claimed from GB0515556A external-priority patent/GB0515556D0/en
Priority claimed from GB0524204A external-priority patent/GB0524204D0/en
Priority claimed from GB0526041A external-priority patent/GB0526041D0/en
Priority claimed from GB0526040A external-priority patent/GB0526040D0/en
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of IL187924A0 publication Critical patent/IL187924A0/en
Publication of IL187924A publication Critical patent/IL187924A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
    • A61K39/0017—Combination vaccines based on whole cell diphtheria-tetanus-pertussis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
    • A61K39/0018—Combination vaccines based on acellular diphtheria-tetanus-pertussis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/116—Polyvalent bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16271—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Otolaryngology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Surgical Instruments (AREA)
IL187924A 2005-06-27 2007-12-06 Immunogenic compositions with n. meningitidis capsular polysaccharides, vaccines and kits including them, processes to make them and their use in manufacture of medicines IL187924A (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GBGB0513071.1A GB0513071D0 (en) 2005-06-27 2005-06-27 Immunogenic composition
GBGB0513069.5A GB0513069D0 (en) 2005-06-27 2005-06-27 Immunogenic composition
GB0515556A GB0515556D0 (en) 2005-07-28 2005-07-28 Immunogenic composition
GB0524204A GB0524204D0 (en) 2005-11-28 2005-11-28 Immunogenic composition
GB0526041A GB0526041D0 (en) 2005-12-21 2005-12-21 Immunogenic composition
GB0526040A GB0526040D0 (en) 2005-12-21 2005-12-21 Immunogenic composition
PCT/EP2006/006188 WO2007000314A2 (en) 2005-06-27 2006-06-23 Immunogenic composition

Publications (2)

Publication Number Publication Date
IL187924A0 IL187924A0 (en) 2008-03-20
IL187924A true IL187924A (en) 2011-11-30

Family

ID=36716943

Family Applications (8)

Application Number Title Priority Date Filing Date
IL187924A IL187924A (en) 2005-06-27 2007-12-06 Immunogenic compositions with n. meningitidis capsular polysaccharides, vaccines and kits including them, processes to make them and their use in manufacture of medicines
IL188046A IL188046A (en) 2005-06-27 2007-12-11 Immunogenic composition comprising at least two different saccharide conjugates
IL188045A IL188045A0 (en) 2005-06-27 2007-12-11 Immunogenic composition
IL188072A IL188072A (en) 2005-06-27 2007-12-12 A method for coupling saccharide to protein carriers by using carboimide compression
IL213718A IL213718A (en) 2005-06-27 2011-06-22 An immunogenic preparation comprising at least two saccharides individually attached to the same type of carrier and compound @ comprising @ the preparation @ the B @ L
IL213795A IL213795A (en) 2005-06-27 2011-06-28 An immunogenic preparation containing at least two different saccharides and a compound containing the aforementioned immunogenic preparation
IL214657A IL214657A0 (en) 2005-06-27 2011-08-15 Immunogenic composition
IL222346A IL222346A (en) 2005-06-27 2012-10-11 An immunogenic preparation containing at least two capsular sugars of meningitides n, its use and a vaccine containing it

Family Applications After (7)

Application Number Title Priority Date Filing Date
IL188046A IL188046A (en) 2005-06-27 2007-12-11 Immunogenic composition comprising at least two different saccharide conjugates
IL188045A IL188045A0 (en) 2005-06-27 2007-12-11 Immunogenic composition
IL188072A IL188072A (en) 2005-06-27 2007-12-12 A method for coupling saccharide to protein carriers by using carboimide compression
IL213718A IL213718A (en) 2005-06-27 2011-06-22 An immunogenic preparation comprising at least two saccharides individually attached to the same type of carrier and compound @ comprising @ the preparation @ the B @ L
IL213795A IL213795A (en) 2005-06-27 2011-06-28 An immunogenic preparation containing at least two different saccharides and a compound containing the aforementioned immunogenic preparation
IL214657A IL214657A0 (en) 2005-06-27 2011-08-15 Immunogenic composition
IL222346A IL222346A (en) 2005-06-27 2012-10-11 An immunogenic preparation containing at least two capsular sugars of meningitides n, its use and a vaccine containing it

Country Status (36)

Country Link
US (13) US8431136B2 (h)
EP (11) EP3009146B1 (h)
JP (9) JP5297800B2 (h)
KR (7) KR101351870B1 (h)
CN (3) CN102526723B (h)
AP (1) AP2436A (h)
AR (3) AR053935A1 (h)
AT (3) ATE462444T1 (h)
AU (7) AU2006263944B2 (h)
BE (1) BE2012C042I2 (h)
BR (5) BRPI0612654B8 (h)
CA (5) CA2611964C (h)
CY (5) CY1109996T1 (h)
DE (1) DE602006013313D1 (h)
DK (7) DK2283857T3 (h)
EA (4) EA012506B1 (h)
ES (9) ES2741529T3 (h)
FR (1) FR22C1008I2 (h)
HR (4) HRP20120102T1 (h)
HU (7) HUE047211T2 (h)
IL (8) IL187924A (h)
LT (2) LT2351578T (h)
LU (2) LU92085I2 (h)
MA (4) MA29603B1 (h)
MX (5) MX2007016236A (h)
MY (3) MY147783A (h)
NL (1) NL300549I2 (h)
NO (4) NO345422B1 (h)
NZ (6) NZ564370A (h)
PE (6) PE20110072A1 (h)
PL (8) PL2283857T3 (h)
PT (8) PT1896065E (h)
SI (8) SI1896062T1 (h)
TW (5) TWI422386B (h)
UA (2) UA95238C2 (h)
WO (6) WO2007000343A2 (h)

Families Citing this family (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002000249A2 (en) * 2000-06-29 2002-01-03 Glaxosmithkline Biologicals S.A. Multivalent vaccine composition
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
PT1587537E (pt) 2003-01-30 2012-05-30 Novartis Ag Vacinas injetáveis contra múltiplos serogrupos meningocócicos
GB0408977D0 (en) * 2004-04-22 2004-05-26 Chiron Srl Immunising against meningococcal serogroup Y using proteins
GB0505518D0 (en) * 2005-03-17 2005-04-27 Chiron Srl Combination vaccines with whole cell pertussis antigen
US7955605B2 (en) * 2005-04-08 2011-06-07 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
BRPI0612654B8 (pt) † 2005-06-27 2021-05-25 Glaxosmithkline Biologicals Sa método para conjugar um sacarídeo a uma proteína, e, conjugado sacarídeo-proteína
AU2012261764B2 (en) * 2005-09-01 2016-09-08 Novartis Vaccines And Diagnostics Gmbh & Co. Kg Multiple vaccination including serogroup C meningococcus
AU2006286228A1 (en) * 2005-09-01 2007-03-08 Novartis Vaccines And Diagnostics Gmbh & Co Kg Multiple vaccination including serogroup C meningococcus
SI1962899T1 (sl) 2005-12-22 2011-11-30 Glaxosmithkline Biolog Sa Pnevmokokna polisaharidna konjugatna vakcina
US10828361B2 (en) * 2006-03-22 2020-11-10 Glaxosmithkline Biologicals Sa Regimens for immunisation with meningococcal conjugates
EP2004225B1 (en) 2006-03-22 2012-04-25 Novartis AG Regimens for immunisation with meningococcal conjugates
GB0612854D0 (en) 2006-06-28 2006-08-09 Novartis Ag Saccharide analysis
CA2662064A1 (en) 2006-09-07 2008-03-13 Glaxosmithkline Biologicals S.A. Method of producing a combination polivirus vaccine
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
GB0700135D0 (en) * 2007-01-04 2007-02-14 Glaxosmithkline Biolog Sa Vaccine
GB0700136D0 (en) 2007-01-04 2007-02-14 Glaxosmithkline Biolog Sa Process for manufacturing vaccines
ES2626662T3 (es) * 2007-06-26 2017-07-25 Glaxosmithkline Biologicals S.A. Vacuna que comprende conjugados de polisacárido capsular de Streptococcus pneumoniae
GB0713880D0 (en) 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
US20160228500A9 (en) * 2007-07-23 2016-08-11 Martina Ochs Immunogenic Polypeptides and Monoclonal Antibodies
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
CN101951949B (zh) 2007-10-19 2013-10-02 诺华股份有限公司 脑膜炎球菌疫苗制剂
CN102202689A (zh) * 2008-08-28 2011-09-28 葛兰素史密丝克莱恩生物有限公司 疫苗
WO2010049806A1 (en) 2008-10-27 2010-05-06 Novartis Ag Purification method
GB0822633D0 (en) 2008-12-11 2009-01-21 Novartis Ag Formulation
GB0822634D0 (en) 2008-12-11 2009-01-21 Novartis Ag Meningitis vaccines
EP2367568A2 (en) 2008-12-17 2011-09-28 Novartis AG Meningococcal vaccines including hemoglobin receptor
AU2010227219B2 (en) 2009-03-24 2014-02-27 Glaxosmithkline Biologicals S.A. Adjuvanting meningococcal factor H binding protein
US20120064103A1 (en) 2009-03-24 2012-03-15 Novartis Ag Combinations of meningococcal factor h binding protein and pneumococcal saccharide conjugates
JP5593626B2 (ja) * 2009-03-31 2014-09-24 凸版印刷株式会社 計量スプーン
CN109248313B (zh) 2009-04-14 2023-01-17 葛兰素史密丝克莱恩生物有限公司 用于免疫接种以抵御金黄色葡萄球菌的组合物
US20120052088A1 (en) * 2009-04-30 2012-03-01 Coley Pharmaceutical Group, Inc. Pneumococcal vaccine and uses thereof
GB0910046D0 (en) * 2009-06-10 2009-07-22 Glaxosmithkline Biolog Sa Novel compositions
AU2010264538B2 (en) 2009-06-22 2013-10-03 Wyeth Llc Immunogenic compositions of Staphylococcus aureus antigens
EP3461496B1 (en) 2009-06-22 2023-08-23 Wyeth LLC Compositions and methods for preparing staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions
US9950062B2 (en) 2009-09-02 2018-04-24 Glaxosmithkline Biologicals Sa Compounds and compositions as TLR activity modulators
SG178904A1 (en) 2009-09-10 2012-04-27 Novartis Ag Combination vaccines against respiratory tract diseases
WO2011051917A1 (en) * 2009-10-30 2011-05-05 Novartis Ag Purification of staphylococcus aureus type 5 and type 8 capsular saccharides
GB0919690D0 (en) 2009-11-10 2009-12-23 Guy S And St Thomas S Nhs Foun compositions for immunising against staphylococcus aureus
EP2519265B1 (en) 2009-12-30 2018-11-14 GlaxoSmithKline Biologicals SA Polysaccharide immunogens conjugated to e. coli carrier proteins
TW201136603A (en) * 2010-02-09 2011-11-01 Merck Sharp & Amp Dohme Corp 15-valent pneumococcal polysaccharide-protein conjugate vaccine composition
GB201003333D0 (en) 2010-02-26 2010-04-14 Novartis Ag Immunogenic proteins and compositions
GB201003922D0 (en) * 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Conjugation process
GB201003924D0 (en) * 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Immunogenic composition
GB201005625D0 (en) 2010-04-01 2010-05-19 Novartis Ag Immunogenic proteins and compositions
WO2011161653A1 (en) 2010-06-25 2011-12-29 Novartis Ag Combinations of meningococcal factor h binding proteins
CN103189071A (zh) 2010-08-23 2013-07-03 惠氏有限责任公司 脑膜炎萘瑟氏菌rLP2086抗原的稳定制剂
US9315530B2 (en) 2010-09-01 2016-04-19 Novartis Ag Adsorption of immunopotentiators to insoluble metal salts
AU2011300418B2 (en) 2010-09-10 2016-05-12 Glaxosmithkline Biologicals Sa Meningococcus overexpressing NadA and/or NHBA and outer membrane vesicles derived therefrom
MX362802B (es) 2010-09-10 2019-02-13 Wyeth Llc Star Variantes no lipidadas de antigenos orf2086 de neisseria meningitidis.
WO2012072769A1 (en) 2010-12-01 2012-06-07 Novartis Ag Pneumococcal rrgb epitopes and clade combinations
ES2681698T3 (es) 2011-03-02 2018-09-14 Glaxosmithkline Biologicals Sa Vacunas de combinación con menores dosis de antígeno y/o adyuvante
GB201114923D0 (en) 2011-08-30 2011-10-12 Novartis Ag Immunogenic proteins and compositions
JP6170932B2 (ja) 2011-11-07 2017-07-26 ノバルティス アーゲー ｓｐｒ００９６抗原およびｓｐｒ２０２１抗原を含むキャリア分子
JP2013112653A (ja) * 2011-11-30 2013-06-10 Jnc Corp 新規重合体およびその製造方法
GB201121301D0 (en) 2011-12-12 2012-01-25 Novartis Ag Method
EP2797624A1 (en) 2011-12-29 2014-11-05 Novartis AG Adjuvanted combinations of meningococcal factor h binding proteins
EP2809349B1 (en) * 2012-01-30 2018-12-19 Serum Institute Of India Private Limited Immunogenic composition
US9657297B2 (en) 2012-02-02 2017-05-23 Glaxosmithkline Biologicals Sa Promoters for increased protein expression in meningococcus
CN102569723A (zh) * 2012-02-13 2012-07-11 华为技术有限公司 锂离子电池正极材料及其制备方法、正极及锂离子电池
CN104519910B (zh) 2012-03-07 2017-05-03 诺华股份有限公司 肺炎链球菌抗原的含佐剂制剂
AU2013229432A1 (en) 2012-03-08 2014-10-16 Novartis Ag Adjuvanted formulations of booster vaccines
CN104159603A (zh) 2012-03-08 2014-11-19 诺华股份有限公司 带有tlr4激动剂的联合疫苗
JP5925342B2 (ja) 2012-03-09 2016-05-25 ファイザー・インク 髄膜炎菌（Ｎｅｉｓｓｅｒｉａｍｅｎｉｎｇｉｔｉｄｉｓ）組成物およびその方法
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
KR102057217B1 (ko) * 2012-06-20 2020-01-22 에스케이바이오사이언스 주식회사 다가 폐렴구균 다당류-단백질 접합체 조성물
MX2015002717A (es) 2012-09-06 2015-05-15 Novartis Ag Vacunas combinadas con meningococo del serogrupo b y toxoides de difteria/tetanos/tosferina.
ITMI20121597A1 (it) * 2012-09-25 2014-03-26 Beta Pharma S A Coniugato tra frammento di parete cellulare batterica ed un veicolo mucopolisaccaridico e suoi usi in ambito medico
AU2013326584B2 (en) 2012-10-02 2016-12-01 Glaxosmithkline Biologicals Sa Nonlinear saccharide conjugates
AU2013351182C1 (en) 2012-11-30 2018-11-08 Glaxosmithkline Biologicals Sa Pseudomonas antigens and antigen combinations
KR20140075196A (ko) 2012-12-11 2014-06-19 에스케이케미칼주식회사 다가 폐렴구균 다당류-단백질 접합체 조성물
CN105007935A (zh) 2012-12-18 2015-10-28 葛兰素史密丝克莱恩生物有限公司 用于保护免于白喉和/或破伤风的缀合物
EP2950819B1 (en) 2013-02-01 2018-03-28 GlaxoSmithKline Biologicals SA Intradermal delivery of immunological compositions comprising toll-like receptor agonists
EP2964665B1 (en) 2013-03-08 2018-08-01 Pfizer Inc Immunogenic fusion polypeptides
BR112015024014A2 (pt) * 2013-03-18 2017-07-18 Glaxosmithkline Biologicals Sa vacina conjugada
EP4098276A1 (en) 2013-09-08 2022-12-07 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
IN2014DE02450A (h) 2013-09-25 2015-06-26 Suzuki Motor Corp
RU2535122C1 (ru) * 2013-11-06 2014-12-10 Федеральное казенное учреждение здравоохранения "Российский научно-исследовательский противочумный институт "Микроб" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека ("РосНИПЧИ "Микроб") Способ получения холерогена-анатоксина
CN110787290B (zh) * 2014-01-21 2024-06-04 辉瑞公司 包含缀合荚膜糖抗原的免疫原性组合物及其用途
US11160855B2 (en) 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
EP2921856B1 (en) 2014-03-18 2016-09-14 Serum Institute Of India Private Limited A quantitative assay for 4-pyrrolidinopyridine (4-ppy) in polysaccharide-protein conjugate vaccines
EP3131576B1 (en) * 2014-04-17 2021-06-30 Medizinische Hochschule Hannover Means and methods for producing neisseria meningitidis capsular polysaccharides of low dispersity
KR20190049940A (ko) 2015-02-19 2019-05-09 화이자 인코포레이티드 나이세리아 메닌지티디스 조성물 및 그의 방법
JP6994453B2 (ja) * 2015-07-21 2022-01-14 ファイザー・インク コンジュゲート化莢膜糖類抗原を含む免疫原性組成物、それを含むキットおよびこれらの使用
US20170333546A1 (en) * 2015-12-08 2017-11-23 Jl Medical Corporation Method for Producing and Vaccine Composition of Neisseria Meningitidis Serogroups A, C, Y, and W-135 Oligosaccharides Conjugated to Glycan-Free Carrier Protein
WO2017158480A1 (en) * 2016-03-15 2017-09-21 Msd Wellcome Trust Hilleman Laboratories Pvt. Ltd. Novel polysaccharide-protein conjugates and process to obtain thereof
WO2018042015A1 (en) 2016-09-02 2018-03-08 Glaxosmithkline Biologicals Sa Vaccines for neisseria gonorrhoeae
EP4309670A3 (en) * 2016-09-02 2024-07-17 Sanofi Pasteur, Inc. Neisseria meningitidis vaccine
AU2017326253B2 (en) 2016-09-13 2021-10-21 Allergan, Inc. Stabilized non-protein clostridial toxin compositions
US11027005B2 (en) * 2016-10-20 2021-06-08 Km Biologics Co., Ltd. Method for producing Hib conjugate vaccine using PRP with lowered molecular weight
US11951165B2 (en) 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
KR20190103256A (ko) 2016-12-30 2019-09-04 수트로박스, 인코포레이티드 비자연 아미노산을 갖는 폴리펩타이드-항원 접합체
PE20191107A1 (es) 2017-01-31 2019-08-26 Pfizer Composiciones de neisseria meningitidis y metodos respectivos
US11524076B2 (en) 2017-09-07 2022-12-13 Merck Sharp & Dohme Llc Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates
CA3074711A1 (en) 2017-09-07 2019-03-14 Merck Sharp & Dohme Corp. Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates
US20200353064A1 (en) * 2018-01-29 2020-11-12 Msd Wellcome Trust Hilleman Laboratories Pvt. Ltd. Novel meningococcal vaccine composition and process thereof
WO2019198096A1 (en) * 2018-04-11 2019-10-17 Msd Wellcome Trust Hilleman Laboratories Pvt. Ltd. Tetravalent meningococcal vaccine composition and process to prepare thereof
JOP20200214A1 (ar) 2019-09-03 2021-03-03 Serum Institute Of India Pvt Ltd تركيبات مولدة للمناعة ضد الأمراض المعوية وطرق لتحضيرها
CA3155669A1 (en) 2019-09-27 2021-04-01 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
US20220387614A1 (en) 2019-11-22 2022-12-08 Glaxosmithkline Biologicals Sa Dosage and administration of a bacterial saccharide glycoconjugate vaccine
US20240000958A1 (en) 2020-11-13 2024-01-04 Glaxosmithkline Biologicals Sa Novel carriers and conjugation methods
RU2770877C1 (ru) * 2021-04-08 2022-04-22 Федеральное бюджетное учреждение науки "Ростовский научно-исследовательский институт микробиологии и паразитологии" Способ получения антигенной конъюгированной субстанции гемофильного типа b микроба для создания вакцинных препаратов
GB202215414D0 (en) 2022-10-18 2022-11-30 Glaxosmithkline Biologicals Sa Vaccine
WO2025021710A1 (en) 2023-07-21 2025-01-30 Glaxosmithkline Biologicals Sa Immunogenic composition

Family Cites Families (184)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB513069A (en) 1937-04-24 1939-10-03 Linde Air Prod Co Improvements in method of and apparatus for the treatment of metallic bodies by oxidising gas
GB505518A (en) 1938-02-03 1939-05-12 Daniel Morgan Skeins Improvements in or relating to envelopes
US4057685A (en) * 1972-02-02 1977-11-08 Abbott Laboratories Chemically modified endotoxin immunizing agent
US4123520A (en) * 1977-08-01 1978-10-31 Merck & Co., Inc. Method for preparing high molecular weight meningococcal Group C vaccine
DE2748132A1 (de) * 1977-10-27 1979-05-03 Behringwerke Ag Stabilisator fuer polysaccharid
US4235994A (en) * 1978-06-26 1980-11-25 Merck & Co., Inc. High molecular weight meningococcal group C vaccine and method for preparation thereof
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
DE3071552D1 (en) 1979-09-21 1986-05-22 Hitachi Ltd Semiconductor switch
DE3040825A1 (de) 1980-10-30 1982-09-09 Dr. Karl Thomae Gmbh, 7950 Biberach Neues tridekapeptid, verfahren zu seiner herstellung und verwendung
US4673574A (en) 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
US4459286A (en) 1983-01-31 1984-07-10 Merck & Co., Inc. Coupled H. influenzae type B vaccine
NL8500370A (nl) * 1984-02-22 1985-09-16 Sandoz Ag Diazepinoindolen, werkwijzen voor hun bereiding en farmaceutische preparaten die ze bevatten.
US4695624A (en) 1984-05-10 1987-09-22 Merck & Co., Inc. Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency
US4808700A (en) 1984-07-09 1989-02-28 Praxis Biologics, Inc. Immunogenic conjugates of non-toxic E. coli LT-B enterotoxin subunit and capsular polymers
US4709017A (en) 1985-06-07 1987-11-24 President And Fellows Of Harvard College Modified toxic vaccines
IT1187753B (it) 1985-07-05 1987-12-23 Sclavo Spa Coniugati glicoproteici ad attivita' immunogenica trivalente
DE3526940A1 (de) 1985-07-27 1987-02-12 Siegfried Fricker Anker zum einbetonieren in schwere lasten
IL78929A0 (en) 1985-07-29 1986-09-30 Abbott Lab Microemulsion compositions for parenteral administration
US4727136A (en) * 1985-10-01 1988-02-23 Canadian Patents And Development Ltd. Modified meningococcal group B polysaccharide for conjugate vaccine
US4950740A (en) 1987-03-17 1990-08-21 Cetus Corporation Recombinant diphtheria vaccines
RU2023448C1 (ru) 1987-07-30 1994-11-30 Сентро Насьональ Де Биопрепарадос Способ получения вакцины против различных патогенных серотипов менингита нейссера группы в
US5180815A (en) 1988-04-13 1993-01-19 Fuji Photo Film Co., Ltd. Modified protein for carrying hapten
JPH03504564A (ja) 1988-05-31 1991-10-09 ベアトリーセ　ケーニッヒ‐ハウク 棚装置
DE3841091A1 (de) 1988-12-07 1990-06-13 Behringwerke Ag Synthetische antigene, verfahren zu ihrer herstellung und ihre verwendung
DE68907045T2 (de) 1989-01-17 1993-12-02 Eniricerche Spa Synthetische Peptide und deren Verwendung als allgemeine Träger für die Herstellung von immunogenischen Konjugaten, die für die Entwicklung von synthetischen Impfstoffen geeignet sind.
WO1991001146A1 (en) 1989-07-14 1991-02-07 Praxis Biologics, Inc. Cytokine and hormone carriers for conjugate vaccines
IT1237764B (it) 1989-11-10 1993-06-17 Eniricerche Spa Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.
RO111416B1 (ro) 1989-12-14 1996-10-31 Ca Nat Research Council Polizaharide modificate de neisseria meningitidis si e coli, combinatii antigenice si metoda de imunizare
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
EP0471177B1 (en) 1990-08-13 1995-10-04 American Cyanamid Company Filamentous hemagglutinin of bordetella pertussis as a carrier molecule for conjugate vaccines
US5153312A (en) 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
CA2059692C (en) 1991-01-28 2004-11-16 Peter J. Kniskern Pneumoccoccal polysaccharide conjugate vaccine
CA2059693C (en) 1991-01-28 2003-08-19 Peter J. Kniskern Polysaccharide antigens from streptococcus pneumoniae
GB2264352A (en) 1992-01-31 1993-08-25 Richards Eng Ltd Incineration apparatus
JP3917172B2 (ja) 1992-02-11 2007-05-23 ヘンリー エム．ジャクソン ファウンデーション フォー ザ アドバンスメント オブ ミリタリー メディスン 二重担体の免疫原性構成体
IT1262896B (it) 1992-03-06 1996-07-22 Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
ES2130265T3 (es) 1992-05-06 1999-07-01 Harvard College Region de union al receptor de la toxina difterica.
NZ253065A (en) 1992-05-23 1996-10-28 Smithkline Beecham Biolog Combination vaccines comprising hepatitis b surface antigens and other antigens wherein aluminium phosphate adjuvant is used to adsorb the hepatitis antigen
IL102687A (en) 1992-07-30 1997-06-10 Yeda Res & Dev Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them
DK0594950T3 (da) 1992-10-27 1999-09-13 American Cyanamid Co Pædiatrisk kombinationsvaccine med forbedret immunogenicitet af hver vaccinekomponent
AU5951894A (en) 1992-12-14 1994-07-04 Western Atlas International, Inc. Removable piston bore liner for hydraulically actuated seismic vibrator
EP0720485B1 (en) 1993-09-22 2003-11-19 Henry M. Jackson Foundation For The Advancement Of Military Medicine Method of activating soluble carbohydrate using novel cyanylating reagents for the production of immunogenic constructs
US5849301A (en) 1993-09-22 1998-12-15 Henry M. Jackson Foundation For The Advancement Of Military Medicine Producing immunogenic constructs using soluable carbohydrates activated via organic cyanylating reagents
DE4416166C2 (de) * 1994-05-06 1997-11-20 Immuno Ag Stabiles Präparat zur Behandlung von Blutgerinnungsstörungen
US5869058A (en) * 1994-05-25 1999-02-09 Yeda Research And Development Co. Ltd. Peptides used as carriers in immunogenic constructs suitable for development of synthetic vaccines
US5917017A (en) 1994-06-08 1999-06-29 President And Fellows Of Harvard College Diphtheria toxin vaccines bearing a mutated R domain
US6455673B1 (en) 1994-06-08 2002-09-24 President And Fellows Of Harvard College Multi-mutant diphtheria toxin vaccines
GB9422096D0 (en) 1994-11-02 1994-12-21 Biocine Spa Combined meningitis vaccine
CA2215933C (en) 1995-03-22 2009-10-13 Andrew Lees Producing immunogenic constructs using soluble carbohydrates activated via organic cyanylating reagents
DE69615362T3 (de) 1995-06-07 2006-07-20 Smithkline Beecham Biologicals S.A. Impfstoff mit einem polysaccharidantigen-trägerprotein-konjugat und einem trägerprotein
CZ288908B6 (cs) 1995-06-23 2001-09-12 Smithkline Beecham Biologicals S. A. Kombinovaná vakcína, tato vakcína ve formě sady, způsob její výroby a její použití
SE9601158D0 (sv) 1996-03-26 1996-03-26 Stefan Svenson Method of producing immunogenic products and vaccines
DE69712219T2 (de) 1996-10-23 2002-12-12 Matsushita Electric Industrial Co., Ltd. Optische platte
PT942983E (pt) 1996-10-31 2007-02-28 Human Genome Sciences Inc Antigénios e vacinas de streptococcus pneumoniae
AU1420897A (en) 1996-12-18 1998-07-15 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Conjugate vaccine for (salmonella paratyphi) a
US6299881B1 (en) 1997-03-24 2001-10-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts
FR2763244B1 (fr) 1997-05-14 2003-08-01 Pasteur Merieux Serums Vacc Composition vaccinale multivalente a porteur mixte
GB9713156D0 (en) 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
GB9717953D0 (en) 1997-08-22 1997-10-29 Smithkline Beecham Biolog Vaccine
DK1028750T3 (da) 1997-09-15 2006-05-22 Sanofi Pasteur Msd Fremgangsmåde til fremstilling af multivalente vacciner
AU9399498A (en) 1997-09-18 1999-04-05 Trustees Of The University Of Pennsylvania, The Receptor-binding pocket mutants of influenza a virus hemagglutinin for use in targeted gene delivery
US5965714A (en) 1997-10-02 1999-10-12 Connaught Laboratories, Inc. Method for the covalent attachment of polysaccharides to protein molecules
US7018637B2 (en) * 1998-02-23 2006-03-28 Aventis Pasteur, Inc Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines
CA2264970A1 (en) 1998-03-10 1999-09-10 American Cyanamid Company Antigenic conjugates of conserved lipolysaccharides of gram negative bacteria
GB9806456D0 (en) 1998-03-25 1998-05-27 Smithkline Beecham Biolog Vaccine composition
GB9808932D0 (en) 1998-04-27 1998-06-24 Chiron Spa Polyepitope carrier protein
EP1073667A2 (en) * 1998-04-28 2001-02-07 Galenica Pharmaceuticals, Inc. Polysaccharide-antigen conjugates
EP1109576B1 (en) 1998-08-19 2009-10-21 Baxter Healthcare SA Immunogenic beta-propionamido-linked polysaccharide protein conjugate useful as a vaccine produced using an n-acryloylated polysaccharide
WO2000033882A1 (en) † 1998-12-04 2000-06-15 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services A vi-repa conjugate vaccine for immunization against salmonella typhi
JP4689044B2 (ja) 1998-12-21 2011-05-25 メディミューン，インコーポレーテッド ワクチン用の肺炎連鎖球菌タンパク質と免疫原断片
US6146902A (en) 1998-12-29 2000-11-14 Aventis Pasteur, Inc. Purification of polysaccharide-protein conjugate vaccines by ultrafiltration with ammonium sulfate solutions
JP2002537102A (ja) 1999-02-26 2002-11-05 カイロン コーポレイション 吸着された高分子および微粒子を有するミクロエマルジョン
PL203917B1 (pl) * 1999-03-19 2009-11-30 Glaxosmithkline Biolog Sa Kompozycja immunogenna, sposób jej wytwarzania oraz zastosowanie
JP2002541808A (ja) 1999-04-09 2002-12-10 テクラブ， インコーポレイテッド ポリサッカリド結合体ワクチンのための組換えトキシンａタンパク質キャリア
MXPA01013253A (es) 1999-06-25 2002-06-04 American Cyanamid Co Produccion de la forma lipidica de las lipoproteinas asociadas a los peptidoglicanos de bacterias gram negativas.
GB9918319D0 (en) 1999-08-03 1999-10-06 Smithkline Beecham Biolog Vaccine composition
GB9925559D0 (en) 1999-10-28 1999-12-29 Smithkline Beecham Biolog Novel method
CA2393298C (en) 1999-12-02 2011-02-01 Chiron Corporation Compositions and methods for stabilizing biological molecules upon lyophilization
FR2806304B1 (fr) * 2000-03-17 2002-05-10 Aventis Pasteur Conjugues polysaccharidiques du pneumocoque a usage vaccinal contre le tetanos et la diphterie
GB0007432D0 (en) 2000-03-27 2000-05-17 Microbiological Res Authority Proteins for use as carriers in conjugate vaccines
GB0108364D0 (en) 2001-04-03 2001-05-23 Glaxosmithkline Biolog Sa Vaccine composition
WO2002000249A2 (en) 2000-06-29 2002-01-03 Glaxosmithkline Biologicals S.A. Multivalent vaccine composition
AU2001280883A1 (en) * 2000-07-27 2002-02-13 The Children's Hospital & Research Center At Oakland Vaccines for broad spectrum protection against diseases caused by neisseria meningitidis
GB0103170D0 (en) * 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
EP2284182A1 (en) * 2000-10-27 2011-02-16 Novartis Vaccines and Diagnostics S.r.l. Nucleic acids and proteins from streptococcus groups A and B
EA006947B1 (ru) * 2001-01-23 2006-06-30 Авентис Пастер Поливалентная менингококковая полисахаридно-белковая конъюгированная вакцина
GB0107661D0 (en) * 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
GB0107658D0 (en) * 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
AU2002309706A1 (en) 2001-05-11 2002-11-25 Aventis Pasteur, Inc. Novel meningitis conjugate vaccine
US6615062B2 (en) 2001-05-31 2003-09-02 Infraredx, Inc. Referencing optical catheters
GB0115176D0 (en) * 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
GB0118249D0 (en) * 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
AR045702A1 (es) * 2001-10-03 2005-11-09 Chiron Corp Composiciones de adyuvantes.
MX339524B (es) * 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
CU23031A1 (es) * 2002-01-24 2005-02-23 Ct Ingenieria Genetica Biotech Antigeno de superficie del virus de la hepatitis b como inmunopotenciador mucosal, formulaciones resultantes
AU2003218162B2 (en) * 2002-03-15 2009-10-29 The Curators Of The University Of Missouri Mutants of the P4 protein of nontypable haemophilus influenzae with reduced enzymatic activity
PT1490409E (pt) 2002-03-26 2009-04-03 Novartis Vaccines & Diagnostic Sacáridos modificados possuindo uma estabilidade melhorada em água
GB0210128D0 (en) * 2002-05-02 2002-06-12 Chiron Spa Nucleic acids and proteins from streptococcus groups A & B
MXPA04011249A (es) * 2002-05-14 2005-06-06 Chiron Srl Vacunas mucosales con adyuvante de quitosano y antigenos meningococicos.
GB0302218D0 (en) * 2003-01-30 2003-03-05 Chiron Sri Vaccine formulation & Mucosal delivery
WO2003094960A2 (en) 2002-05-14 2003-11-20 Chiron Srl Mucosal combination vaccines for bacterial meningitis
GB0211118D0 (en) * 2002-05-15 2002-06-26 Polonelli Luciano Vaccines
US20040096461A1 (en) 2002-07-30 2004-05-20 Baxter Healthcare Corporation Chimeric multivalent polysaccharide conjugate vaccines
GB0220199D0 (en) * 2002-08-30 2002-10-09 Univ Utrecht Mutant protein and refolding method
SI1524993T1 (sl) 2002-08-02 2013-07-31 Glaxosmithkline Biologicals S.A. Neisserijski vakcinski sestavki, ki obsegajo kombinacijo antigenov
GB0220194D0 (en) * 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
CN1809380B (zh) 2002-10-11 2010-05-12 启龙有限公司 广泛防御高毒性脑膜炎球菌谱系的多肽-疫苗
CN1401328A (zh) 2002-10-18 2003-03-12 北京绿竹生物技术有限责任公司 流行性脑脊髓膜炎多糖－蛋白结合疫苗
MY145693A (en) * 2002-11-01 2012-03-30 Glaxosmithkline Biolog Sa A method of drying without freezing or bubbling
GB0227346D0 (en) * 2002-11-22 2002-12-31 Chiron Spa 741
CN1168501C (zh) 2002-12-27 2004-09-29 北京绿竹生物技术有限责任公司 一种多糖-蛋白结合疫苗
PT1587537E (pt) 2003-01-30 2012-05-30 Novartis Ag Vacinas injetáveis contra múltiplos serogrupos meningocócicos
BRPI0408094A (pt) * 2003-03-13 2006-02-14 Glaxosmithkline Biolog Sa processo para purificação de uma citolisina bacteriana, citolisina bacteriana, conjugado de polissacarìdeo capsular-pneumolisina bacteriano, composição imunogênica, vacina, processo de produção da vacina, método de tratamento ou prevenção de infecção por streptococcus pneumoniae, e, uso da pneumolisina ou do conjugado de polissacarìdeo-pneumolisina bacteriano
CA2519511A1 (en) 2003-03-17 2004-09-30 Wyeth Holdings Corporation Mutant cholera holotoxin as an adjuvant and an antigen carrier protein
CN1852733A (zh) * 2003-05-07 2006-10-25 安万特巴斯德公司 多价脑膜炎球菌衍生的多糖－蛋白质缀合物及疫苗
CN1798548B (zh) 2003-06-02 2010-05-05 诺华疫苗和诊断公司 基于含吸附类毒素和含多糖抗原微粒体的免疫原性组合物
GB0313916D0 (en) * 2003-06-16 2003-07-23 Glaxosmithkline Biolog Sa Vaccine composition
EP2364725A3 (en) 2003-06-23 2012-05-09 Sanofi Pasteur Inc. Immunization method against neisseria meningitidis serogroups a and c
KR101034055B1 (ko) 2003-07-18 2011-05-12 엘지이노텍 주식회사 발광 다이오드 및 그 제조방법
EP1651262A2 (en) * 2003-08-06 2006-05-03 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Process for preparing polysaccharide-protein conjugate vaccines
US8048432B2 (en) * 2003-08-06 2011-11-01 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Polysaccharide-protein conjugate vaccines
US6995363B2 (en) * 2003-08-21 2006-02-07 Applera Corporation Reduction of matrix interference for MALDI mass spectrometry analysis
CA2539715C (en) * 2003-10-02 2015-02-24 Glaxosmithkline Biologicals S.A. Pertussis antigens and use thereof in vaccination
NZ546430A (en) * 2003-10-02 2009-04-30 Novartis Vaccines & Diagnostic Liquid vaccines for multiple meningococcal serogroups
CA2550927A1 (en) * 2003-12-23 2005-07-14 Glaxosmithkline Biologicals S.A. A gram negative bacterium with reduced lps level in the outer membrane and use thereof for treating gram negative bacterial infection
GB0405787D0 (en) * 2004-03-15 2004-04-21 Chiron Srl Low dose vaccines
KR20070008625A (ko) * 2004-04-05 2007-01-17 화이자 프로덕츠 인코포레이티드 미세유체화된 수중유 유화액 및 백신 조성물
GB0409745D0 (en) * 2004-04-30 2004-06-09 Chiron Srl Compositions including unconjugated carrier proteins
GB0500787D0 (en) 2005-01-14 2005-02-23 Chiron Srl Integration of meningococcal conjugate vaccination
AU2005237289B2 (en) 2004-04-30 2011-08-04 Glaxosmithkline Biologicals S.A. Meningococcal conjugate vaccination
GB0413868D0 (en) * 2004-06-21 2004-07-21 Chiron Srl Dimensional anlaysis of saccharide conjugates
EP1793849A2 (en) * 2004-09-22 2007-06-13 GlaxoSmithKline Biologicals SA Immunogenic composition for use in vaccination against staphylococcei
US20060121055A1 (en) 2004-12-06 2006-06-08 Becton, Dickinson And Company, Inc. Compositions with enhanced immunogenicity
GB0428394D0 (en) 2004-12-24 2005-02-02 Chiron Srl Saccharide conjugate vaccines
GB0502095D0 (en) 2005-02-01 2005-03-09 Chiron Srl Conjugation of streptococcal capsular saccharides
EP2351772B1 (en) * 2005-02-18 2016-07-13 GlaxoSmithKline Biologicals SA Proteins and nucleic acids from meningitis/sepsis-associated Escherichia coli
GB0505518D0 (en) 2005-03-17 2005-04-27 Chiron Srl Combination vaccines with whole cell pertussis antigen
DK1868645T3 (da) 2005-04-08 2012-04-10 Wyeth Llc Multivalent pneumokok-sakkarid-protein-konjugat-sammensætning
US20070184072A1 (en) * 2005-04-08 2007-08-09 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
CN101282984B (zh) * 2005-05-06 2013-05-08 诺华疫苗与诊断股份有限公司 A型脑膜炎疫苗的免疫原
BRPI0612654B8 (pt) 2005-06-27 2021-05-25 Glaxosmithkline Biologicals Sa método para conjugar um sacarídeo a uma proteína, e, conjugado sacarídeo-proteína
CN1709505B (zh) 2005-07-13 2010-06-16 北京绿竹生物制药有限公司 多价细菌荚膜多糖-蛋白质结合物联合疫苗
AU2006286228A1 (en) * 2005-09-01 2007-03-08 Novartis Vaccines And Diagnostics Gmbh & Co Kg Multiple vaccination including serogroup C meningococcus
JP5047969B2 (ja) * 2005-09-05 2012-10-10 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 髄膜炎菌特異的抗血清に対する血清殺菌アッセイ
GB0522765D0 (en) * 2005-11-08 2005-12-14 Chiron Srl Combination vaccine manufacture
SI1962899T1 (sl) 2005-12-22 2011-11-30 Glaxosmithkline Biolog Sa Pnevmokokna polisaharidna konjugatna vakcina
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
BRPI0620418A2 (pt) 2005-12-23 2011-11-08 Glaxosmithkline Biolog Sa método para imunizar um paciente humano contra uma doença, usos de pelo menos dois e de pelo menos sete, dez, onze, treze ou quatorze conjugados e das vacinas, e, kit
EP3006041B1 (en) * 2006-03-17 2017-11-29 The Government of the United States of America, as represented by The Secretary, Department of Health and Human Services Methods for preparing complex multivalent immunogenic conjugates
AR060187A1 (es) * 2006-03-30 2008-05-28 Glaxosmithkline Biolog Sa Composicion inmunogenica
EP2476433A1 (en) * 2006-03-30 2012-07-18 GlaxoSmithKline Biologicals S.A. Immunogenic composition
BRPI0713904A2 (pt) * 2006-06-29 2013-06-25 Novartis Ag polipeptÍdeos a partir de neisseria meningitidis
US7491517B2 (en) * 2006-07-19 2009-02-17 Jeeri R Reddy Method of producing meningococcal meningitis vaccine for Neisseria meningitidis serotypes A,C,Y, and W-135
US20080171061A1 (en) 2006-07-21 2008-07-17 Douglas Nixon Human endogenous retrovirus polypeptide compositions and methods of use thereof
CA2662064A1 (en) * 2006-09-07 2008-03-13 Glaxosmithkline Biologicals S.A. Method of producing a combination polivirus vaccine
GB0700135D0 (en) 2007-01-04 2007-02-14 Glaxosmithkline Biolog Sa Vaccine
GB0700136D0 (en) * 2007-01-04 2007-02-14 Glaxosmithkline Biolog Sa Process for manufacturing vaccines
WO2008111374A1 (ja) * 2007-03-14 2008-09-18 Konica Minolta Business Technologies, Inc. 情報埋め込み方法、そのプログラムおよび情報埋め込み装置
EA201490303A1 (ru) * 2007-05-02 2014-05-30 Глаксосмитклайн Байолоджикалс С.А. Вакцина
RU2009149359A (ru) 2007-06-04 2011-07-20 Новартис АГ (CH) Состав вакцин против менингита
ES2626662T3 (es) 2007-06-26 2017-07-25 Glaxosmithkline Biologicals S.A. Vacuna que comprende conjugados de polisacárido capsular de Streptococcus pneumoniae
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
CN102202689A (zh) * 2008-08-28 2011-09-28 葛兰素史密丝克莱恩生物有限公司 疫苗
GB0816447D0 (en) * 2008-09-08 2008-10-15 Glaxosmithkline Biolog Sa Vaccine
US8259461B2 (en) * 2008-11-25 2012-09-04 Micron Technology, Inc. Apparatus for bypassing faulty connections
CN102596254B (zh) * 2009-09-30 2016-10-19 诺华股份有限公司 金黄色葡萄球菌5型和8型荚膜多糖的偶联
TW201136603A (en) * 2010-02-09 2011-11-01 Merck Sharp & Amp Dohme Corp 15-valent pneumococcal polysaccharide-protein conjugate vaccine composition
GB201003922D0 (en) * 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Conjugation process
BR112012022800A2 (pt) * 2010-03-11 2018-05-15 Glaxosmithkline Biologicals Sa composição imunogênica ou vacina, cepa bacteriana gram-negativa geneticamente engenheirada, métodos para o tratamento ou prevenção de infecção ou doença, para produzir uma composição imunogênica ou uma vacina, e para preparar uma imunoglobulina, preparação da imunoglobulina, e, preparação farmacêutica
CN102781322B (zh) * 2010-06-11 2015-02-25 松下电器产业株式会社 语音听取的评价系统、及方法
JP6170932B2 (ja) * 2011-11-07 2017-07-26 ノバルティス アーゲー ｓｐｒ００９６抗原およびｓｐｒ２０２１抗原を含むキャリア分子
GB2495341B (en) * 2011-11-11 2013-09-18 Novartis Ag Fermentation methods and their products
EP2809349B1 (en) * 2012-01-30 2018-12-19 Serum Institute Of India Private Limited Immunogenic composition
US10124051B2 (en) * 2012-05-22 2018-11-13 Glaxosmithkline Biologicals Sa Meningococcus serogroup X conjugate
WO2014001328A1 (en) 2012-06-25 2014-01-03 Nadiro A/S A lifeboat deployment unit
HRP20230359T1 (hr) * 2012-12-05 2023-06-09 Glaxosmithkline Biologicals Sa Imunogeni pripravak
GB201310008D0 (en) * 2013-06-05 2013-07-17 Glaxosmithkline Biolog Sa Immunogenic composition for use in therapy
SG11201700673RA (en) * 2014-08-05 2017-02-27 Glaxosmithkline Biolog Sa Carrier molecule for antigens
TWI715617B (zh) * 2015-08-24 2021-01-11 比利時商葛蘭素史密斯克藍生物品公司 對抗腸道外病原性大腸桿菌之免疫保護之方法及組合物
GB201518684D0 (en) * 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Vaccine
EP4309670A3 (en) * 2016-09-02 2024-07-17 Sanofi Pasteur, Inc. Neisseria meningitidis vaccine
US11951165B2 (en) * 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
PE20191107A1 (es) * 2017-01-31 2019-08-26 Pfizer Composiciones de neisseria meningitidis y metodos respectivos
UA128204C2 (uk) * 2017-07-18 2024-05-08 Сірем Інстітьют Оф Індіа Пвт Лтд. Імуногенна композиція з покращеною стабільністю, підвищеною імуногенністю та зниженою реактогенністю і спосіб її виготовлення

Also Published As

Publication number Publication date
EP2878307A1 (en) 2015-06-03
SI2283857T1 (sl) 2019-11-29
AU2010212417A1 (en) 2010-09-09
US8329184B2 (en) 2012-12-11
JP2008543908A (ja) 2008-12-04
BRPI0612669A2 (pt) 2010-11-30
HRP20120102T1 (hr) 2012-02-29
AR053935A1 (es) 2007-05-23
UA95238C2 (uk) 2011-07-25
SI1896065T1 (sl) 2011-10-28
HK1116414A1 (en) 2008-12-24
LTPA2012019I1 (lt) 2012-11-26
UA95237C2 (uk) 2011-07-25
PE20110096A1 (es) 2011-03-07
KR20080030577A (ko) 2008-04-04
HRP20110567T4 (xx) 2015-01-16
HUE047211T2 (hu) 2020-04-28
PL1896061T3 (pl) 2020-02-28
AU2006263944B2 (en) 2012-03-01
IL222346A (en) 2015-07-30
TW201336507A (zh) 2013-09-16
IL188072A (en) 2017-07-31
NO20076363L (no) 2008-03-26
EP1896065B1 (en) 2011-07-20
HK1116413A1 (en) 2008-12-24
NL300549I2 (h) 2017-01-03
BRPI0612669B8 (pt) 2021-05-25
DK1896061T3 (da) 2019-08-26
EP2201961A1 (en) 2010-06-30
BRPI0612655A8 (pt) 2018-01-30
SI2351578T1 (sl) 2017-05-31
JP2008543907A (ja) 2008-12-04
NO345422B1 (no) 2021-01-25
IL213718A (en) 2013-07-31
JP2008543905A (ja) 2008-12-04
AR056397A1 (es) 2007-10-10
NO342815B1 (no) 2018-08-13
IL214657A0 (en) 2011-09-27
EP1896066A2 (en) 2008-03-12
JP5297800B2 (ja) 2013-09-25
NO20076343L (no) 2008-03-25
AU2010203115B2 (en) 2012-03-15
US20150044253A1 (en) 2015-02-12
PL3009146T3 (pl) 2022-02-07
IL188072A0 (en) 2008-03-20
HUS1200023I1 (hu) 2021-03-29
SI1896061T1 (sl) 2019-10-30
DE602006013313D1 (de) 2010-05-12
MY147490A (en) 2012-12-14
HRP20110567T1 (en) 2011-09-30
WO2007000342A2 (en) 2007-01-04
WO2007000314A3 (en) 2007-05-31
MA29569B1 (fr) 2008-06-02
JP2015134829A (ja) 2015-07-27
US10245317B2 (en) 2019-04-02
US20100215686A1 (en) 2010-08-26
HRP20100211T1 (hr) 2010-05-31
KR20080018226A (ko) 2008-02-27
BRPI0612654B1 (pt) 2021-05-04
AU2006263944A1 (en) 2007-01-04
ES2377075T3 (es) 2012-03-22
WO2007000342A3 (en) 2007-05-31
MA29603B1 (fr) 2008-07-01
EP2351578B1 (en) 2017-01-18
BRPI0612656A2 (pt) 2010-11-30
PT2283857T (pt) 2019-10-24
JP2008543909A (ja) 2008-12-04
PL2351578T3 (pl) 2017-07-31
MX2007016237A (es) 2008-03-07
AU2006263936A1 (en) 2007-01-04
AU2006263964B2 (en) 2010-05-20
WO2007000342A8 (en) 2008-07-10
AR056396A1 (es) 2007-10-10
BRPI0612656A8 (pt) 2018-01-23
US11241495B2 (en) 2022-02-08
PE20070123A1 (es) 2007-02-08
IL213795A (en) 2013-05-30
JP2013107913A (ja) 2013-06-06
DK2351578T3 (en) 2017-04-24
TW200738259A (en) 2007-10-16
NO344452B1 (no) 2019-12-09
WO2007000343A2 (en) 2007-01-04
CY1112698T1 (el) 2016-02-10
ES2662651T3 (es) 2018-04-09
KR20080025184A (ko) 2008-03-19
FR22C1008I2 (fr) 2024-01-19
US9789179B2 (en) 2017-10-17
PL1896065T5 (pl) 2014-12-31
TWI477283B (zh) 2015-03-21
KR101321056B1 (ko) 2013-10-30
BRPI0612670B8 (pt) 2021-05-25
AU2006263965B2 (en) 2012-09-13
BRPI0612655B1 (pt) 2021-06-15
HUS000497I2 (hu) 2021-03-29
DK1896063T3 (da) 2012-03-19
ES2901378T3 (es) 2022-03-22
PL1896063T3 (pl) 2012-04-30
PT1896061T (pt) 2019-08-01
BRPI0612670B1 (pt) 2020-04-28
PE20142165A1 (es) 2015-01-09
US20170065714A1 (en) 2017-03-09
WO2007000341A3 (en) 2007-05-31
US20090041802A1 (en) 2009-02-12
NZ564607A (en) 2011-06-30
DK2878307T3 (da) 2019-10-07
CN103083657A (zh) 2013-05-08
EA200702574A1 (ru) 2008-06-30
US8431136B2 (en) 2013-04-30
KR20080018216A (ko) 2008-02-27
PT2351578T (pt) 2017-04-07
HRP20170457T1 (hr) 2017-05-19
EP2878307B1 (en) 2019-07-24
EP1896063B1 (en) 2011-12-14
WO2007000322A1 (en) 2007-01-04
AU2010203115A1 (en) 2010-08-12
CY1111827T1 (el) 2015-10-07
AU2006263936B2 (en) 2010-05-20
AU2010203115C1 (en) 2013-05-02
HUE046905T2 (hu) 2020-03-30
WO2007000343A3 (en) 2007-05-31
TWI422386B (zh) 2014-01-11
DK1896062T3 (da) 2010-06-28
JP5769688B2 (ja) 2015-08-26
NZ590204A (en) 2012-02-24
WO2007000314A2 (en) 2007-01-04
IL188046A0 (en) 2008-03-20
PT3009146T (pt) 2021-11-30
CN102218138A (zh) 2011-10-19
AU2006263963A1 (en) 2007-01-04
CA2611960C (en) 2015-05-05
ATE462444T1 (de) 2010-04-15
KR101351873B1 (ko) 2014-02-17
ATE536884T1 (de) 2011-12-15
ES2340711T3 (es) 2010-06-08
IL188045A0 (en) 2008-03-20
EA012214B1 (ru) 2009-08-28
EP1896066B8 (en) 2022-01-19
EP1896062B1 (en) 2010-03-31
EP3009146B1 (en) 2021-10-20
US20090136541A1 (en) 2009-05-28
MX2007016405A (es) 2008-03-07
JP5718960B2 (ja) 2015-05-13
US20130171188A1 (en) 2013-07-04
BRPI0612655A2 (pt) 2010-11-30
TW200730187A (en) 2007-08-16
US8846049B2 (en) 2014-09-30
MA29602B1 (fr) 2008-07-01
DK1896065T4 (da) 2014-10-20
HUE056842T2 (hu) 2022-03-28
EP2351578A1 (en) 2011-08-03
EP1896064A2 (en) 2008-03-12
EA200702577A1 (ru) 2008-06-30
US20090252759A1 (en) 2009-10-08
US20130004532A1 (en) 2013-01-03
LUC00247I2 (h) 2024-10-04
HUE045482T2 (hu) 2019-12-30
SI1896062T1 (sl) 2010-07-30
NZ564606A (en) 2010-10-29
NO345305B1 (no) 2020-12-07
US20200000911A1 (en) 2020-01-02
WO2007000327A1 (en) 2007-01-04
NO20076350L (no) 2008-03-26
KR20130086087A (ko) 2013-07-30
PE20110072A1 (es) 2011-02-04
JP2008543904A (ja) 2008-12-04
LT2351578T (lt) 2017-04-10
EA013374B1 (ru) 2010-04-30
PL1896062T3 (pl) 2010-08-31
IL188046A (en) 2012-03-29
HK1206587A1 (en) 2016-01-15
US20180064806A1 (en) 2018-03-08
CY2012027I2 (el) 2015-10-07
ES2898451T3 (es) 2022-03-07
EA012528B1 (ru) 2009-10-30
PT1896062E (pt) 2010-05-17
ATE516816T1 (de) 2011-08-15
BE2012C042I2 (h) 2021-07-19
BRPI0612654B8 (pt) 2021-05-25
LU92085I2 (fr) 2012-12-19
SI2878307T1 (sl) 2019-11-29
JP5731737B2 (ja) 2015-06-10
PT1896063E (pt) 2012-02-13
EP3009146A1 (en) 2016-04-20
US20080193476A1 (en) 2008-08-14
CA2612957C (en) 2016-07-19
CN103083657B (zh) 2016-06-08
US8398983B2 (en) 2013-03-19
MX2007016236A (es) 2008-03-07
AU2006263964A1 (en) 2007-01-04
HUS2200002I1 (hu) 2022-12-28
ES2377075T5 (es) 2016-04-29
CA2611964A1 (en) 2007-01-04
TW201414490A (zh) 2014-04-16
BRPI0612669B1 (pt) 2019-08-13
JP5037503B2 (ja) 2012-09-26
CA2612957A1 (en) 2007-01-04
EP1896061B1 (en) 2019-06-12
ES2621780T3 (es) 2017-07-05
US10166287B2 (en) 2019-01-01
EP2283857A1 (en) 2011-02-16
NZ564370A (en) 2011-10-28
IL213795A0 (en) 2011-07-31
DK2283857T3 (da) 2019-10-28
MA29993B1 (fr) 2008-12-01
US20190298822A1 (en) 2019-10-03
NO20076302L (no) 2008-03-26
PL2878307T3 (pl) 2020-01-31
FR22C1008I1 (fr) 2022-04-29
SI1896065T2 (sl) 2014-12-31
PL1896065T3 (pl) 2011-12-30
PL2283857T3 (pl) 2020-02-28
IL213718A0 (en) 2011-07-31
AU2006263965A1 (en) 2007-01-04
LTC1896065I2 (lt) 2025-06-10
EA200702575A1 (ru) 2008-06-30
CY2012027I1 (el) 2015-10-07
CN102526723B (zh) 2017-07-07
AU2006263963B2 (en) 2010-05-13
CN102526723A (zh) 2012-07-04
AP2436A (en) 2012-08-31
EP1896062A1 (en) 2008-03-12
TWI537001B (zh) 2016-06-11
BRPI0612670A2 (pt) 2010-11-30
CY1109996T1 (el) 2014-09-10
KR20130122810A (ko) 2013-11-08
BRPI0612654A2 (pt) 2012-10-02
JP2013018798A (ja) 2013-01-31
KR101359953B1 (ko) 2014-02-21
MY147783A (en) 2013-01-31
SI3009146T1 (sl) 2022-02-28
KR20080024222A (ko) 2008-03-17
JP5965512B2 (ja) 2016-08-03
EP1896063A1 (en) 2008-03-12
US9486515B2 (en) 2016-11-08
KR101532068B1 (ko) 2015-06-29
MY148110A (en) 2013-02-28
EP2283857B1 (en) 2019-07-24
US9358279B2 (en) 2016-06-07
LU92085I9 (h) 2019-01-04
MX2007016402A (es) 2008-03-07
MX2007016403A (es) 2008-03-07
CA2611960A1 (en) 2007-01-04
CA2612980C (en) 2019-01-15
JP2013209395A (ja) 2013-10-10
AP2007004274A0 (en) 2007-12-31
WO2007000341A2 (en) 2007-01-04
EP1896063B2 (en) 2016-03-02
NZ564371A (en) 2010-05-28
ES2750243T3 (es) 2020-03-25
IL187924A0 (en) 2008-03-20
US8883163B2 (en) 2014-11-11
EA012506B1 (ru) 2009-10-30
CA2612980A1 (en) 2007-01-04
SI1896063T1 (sl) 2012-03-30
EP1896061A2 (en) 2008-03-12
DK1896065T3 (da) 2011-08-29
PE20070499A1 (es) 2007-05-21
BRPI0612656B1 (pt) 2021-09-08
EP1896065A2 (en) 2008-03-12
KR101408113B1 (ko) 2014-06-16
EP1896065B2 (en) 2014-09-03
CY1118646T1 (el) 2017-07-12
ES2747025T3 (es) 2020-03-09
CA2612963C (en) 2016-10-18
TWI407970B (zh) 2013-09-11
EP2201961B1 (en) 2018-01-24
NZ564605A (en) 2011-01-28
PT1896065E (pt) 2011-08-31
US20080199490A1 (en) 2008-08-21
KR101351870B1 (ko) 2014-02-17
US9931397B2 (en) 2018-04-03
HUE031380T2 (en) 2017-07-28
EP1896066B1 (en) 2021-10-27
CA2612963A1 (en) 2007-01-04
EA200702576A1 (ru) 2008-06-30
PT2878307T (pt) 2019-10-24
JP5280199B2 (ja) 2013-09-04
CA2611964C (en) 2016-11-08
ES2741529T3 (es) 2020-02-11
HK1114011A1 (en) 2008-10-24
PE20070163A1 (es) 2007-03-01

Similar Documents

Publication Publication Date Title
US11241495B2 (en) Immunogenic composition
CN101222935B (zh) 免疫原性组合物
AU2012203419B2 (en) Immunogenic composition
HK1116082B (en) Immunogenic composition
HK1116082A (en) Immunogenic composition
HK1206587B (en) Immunogenic composition
HK1116412B (en) Immunogenic composition

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
KB Patent renewed